Human papillomavirus infection in “young” versus “old” patients with squamous cell carcinoma of the head and neck by Sisk, Elizabeth A. et al.
HUMAN PAPILLOMAVIRUS INFECTION IN “YOUNG”
VERSUS “OLD” PATIENTS WITH SQUAMOUS CELL
CARCINOMA OF THE HEAD AND NECK
Elizabeth A. Sisk, MD, 1 Carol R. Bradford, MD, FACS, 1 Abraham Jacob, MD, 1*
Christopher H. Yian, MD, 1* Kim M. Staton, MD, 1† Gong Tang, MS, 2 Monte O. Harris, MD, 1
Thomas E. Carey, PhD, 1 Wayne D. Lancaster, PhD, 3,4 Lucie Gregoire, PhD 4
1 Department of Otolaryngology/Head and Neck Surgery, The University of Michigan, 1904 Taubman Center,
1500 E. Medical Center Drive, Ann Arbor, Michigan 48109
2 Department of Biostatistics, The University of Michigan, Ann Arbor, Michigan
3 Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan 48201
4 Center for Molecular Genetics, Wayne State University, Detroit, Michigan
Accepted 20 December 1999
Abstract: Background. Human papillomavirus (HPV) repre-
sents a potential risk factor for squamous cell cancer of the head
and neck (SCCHN). We evaluated the prevalence of HPV DNA in
patients with SCCHN diagnosed at the University of Michigan
from 1994–1996.
Methods. Patients were stratified by age at diagnosis as
“young” (<50 years; median, 39) or “old” (>50 years; median, 66).
Fourteen “young” and 14 “old” were matched for tumor site, and
4 additional “old” patients were included. Specimens were ana-
lyzed by polymerase chain reaction for HPV DNA using 2 sets of
consensus primers. HPV sequences were confirmed by Southern
blot hybridization and typed with type-specific probes.
Results. Overall, 15 of 32 (46.9%) samples contained HPV
sequences. HPV 16 was detected in 9 of 15 (60%), HPV-18 in 1
of 15 (6.6%), and 5 of 15 (33.3%) remained untyped by multiple
methods. When stratified, 7 of 14 (50%) “young” were HPV-
positive compared with 8 of 18 (44.4%) “old” (p = .76). Survival in
patients with HPV-positive SCCHN was significantly longer than
that for HPV-negative patients.
Conclusions. The incidence of HPV in “young” versus “old” is
not significantly different, suggesting similar roles for both
groups. Patients with HPV-positive tumors may have a survival
advantage relative to patients with HPV-negative tumors. © 2000
John Wiley & Sons, Inc. Head Neck 22: 649–657, 2000.
Keywords: neoplasms; head and neck human papillomavirus;
squamous cell carcinoma
Increasing evidence exists to support the role of
human papillomavirus (HPV) in the development
of squamous cell carcinoma of the head and neck
(SCCHN). Although the role is less clear in head
and neck cancer (HNC) than for cervical cancer,
HPV DNA has been identified in primary tumors
of the tonsil,1,2 larynx,3 hypopharynx,3 oral cav-
ity,4 tongue,5 nasopharynx,6 in cell lines derived
from a variety of head and neck carcinomas,7 and
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in inverted papillomas that have progressed to
SCC.8 Precancerous lesions9 and metastatic
lymph nodes1,10 have also been shown to contain
DNA of the same HPV type as the primary tumor,
supporting the involvement of HPV in the devel-
opment of SCC. A recent review indicates the de-
tection of HPV DNA varies widely from 0% to
100%, depending on the site examined and meth-
ods used.11 Most commonly the “high-risk” HPV
types 16 and 18 are involved; however, types 2, 3,
6, 7, 11, 13, 31, 33, 35, 45, 52, 57, and 5910–12 have
also been detected.
As increasing attention has been given to the
possible role of HPV in the development of SC-
CHN, recent reports have also described an in-
crease in SCCHN in young adults.13 This has tre-
mendous societal implications in a young
population because the disease may be mutilating
and fatal. Controversy exists concerning the prog-
nosis and treatment of these young patients. One
report found higher local-regional failure and
mortality rate than a representative older popu-
lation14 and therefore recommended aggressive
treatment of young adults. Another study con-
curred as it found young patients to have highly
invasive lesions with early spread to lymph
nodes.15 However, several other studies have
failed to detect a higher likelihood of recur-
rence11,13 or a difference in survival16,17 relative
to older patients, leading one group to conclude
that more aggressive treatment is not war-
ranted.17
Regardless of the prognosis, most clinicians
believe that young patients with SCCHN make
up a distinct subset of HNC patients perhaps
with novel risk factors. The association between
tobacco and alcohol exposure in SCCHN in
older patients is well documented. However,
many studies have demonstrated a lack of com-
mon HNC-related habits among younger pa-
tients.15,18,19 Unlike older patients with HNC
who are predominantly men, young patients have
a higher proportion of women15,17 Tumor sites
may also vary by age, with an increase in tongue
or oral cavity tumors in the young group.14,16,17
The preceding differences suggest that young
patients with SCCHN represent an etiologically
and/or biologically distinct group of patients. Ge-
netic disorders, immunodeficiency or altered im-
mune responses, greater DNA fragility, and in-
creasing sensitivity to carcinogens have all been
proposed as carcinogenic mechanisms.13 How-
ever, no single theory has proved to be conclusive.
Although HPV has been studied as a possible risk
factor for the development of SCCHN, the role of
HPV in young patients with SCCHN has not been
determined. In this study we attempt to address
this question by determining the prevalence of
HPV DNA in SCCHN specimens from both
“young” (age <50) and “old” (age >50) patients. In
addition, we will analyze the relationship be-
tween the presence of HPV DNA and risk factor
exposure, site and stage of disease, and outcome
in this group of patients. Thus, we hope to gain
more insight into the role of and mechanism of
HPV in SCCHN in all age groups.
MATERIALS AND METHODS
Tumor Specimens. Tumor specimens were ob-
tained from patients with SCCHN diagnosed at
the University of Michigan from 1994–1996. In-
stitutional review board approval was obtained
from our institution, and all patients completed
informed consent documents. Patients were
stratified by age at diagnosis as “young” (age <50)
or “old” (age >50). Fourteen “young” and 14 “old”
patients were matched for tumor site, and 4 ad-
ditional “old” patients were included. No patients
had a history of respiratory papillomatosis. Ret-
rospective chart review was performed to obtain
pertinent clinical information, including tobacco
and alcohol exposure, tumor stage at the time of
diagnosis, outcome, and survival data. Because of
the retrospective nature of the study, alcohol and
tobacco use could not be quantitatively reported.
Tobacco use was defined as “yes” for any current
or previous use, and alcohol consumption was
roughly divided into “none,” “occasional,” and
“frequent” on the basis of consumption at the time
of presentation or recent level of consumption if
the patient has ceased drinking. Stage was deter-
mined on pathologic data.
DNA Extraction. Specimens were procured at the
time of surgery, immediately snap frozen in liquid
nitrogen, and stored at −70°C until the time of
DNA extraction. Frozen specimens were serially
sectioned with a cryostat at 10 mm intervals with
approximately 40 sections used per specimen.
The first and last sections were H & E stained for
histopathologic review. Sections consisting of <70%
SCC cells were enriched by microdissection. DNA
extraction was then accomplished by use of the
Nucleon II DNA Extraction Kit (Scotlab, Scotland).
Detection of HPV DNA by PCR. Before performing
polymerase chain reaction (PCR) with the prim-
ers of interest, control PCR reactions were suc-
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cessfully performed on all samples with b-globin
primers as previously described19 to ensure the
presence of amplifiable DNA. All reactions used a
positive control (HPV 4 plasmid or Caski cell
lines), a negative control (“cell line 293”), and dis-
tilled water as a reagent control. To prevent con-
tamination among samples, PCR reactions were
set up in a physically separated room designated
for pre-PCR work only, pipettors were soaked in a
10% bleach solution before use, and PCR reaction
mixtures were irradiated with UV light before ad-
dition of sample DNA and Taq DNA polymerase.
Specimens were analyzed by PCR for the pres-
ence of HPV DNA by use of two different consen-
sus primer sets derived from the E1 open reading
frame (ORF) and the L1 ORF (Fig. 1). PCR with
the E1 primer set (IU and IWDO) generates an
850 base pair fragment and was slightly modified
from that described by Gregoire et al.20 A 50-mL
reaction mixture was used consisting of 0.5 mg of
sample DNA, 2.0 mM MgCl2, 200 mM of each
dNTP, 1 mM of each primer (IU and IWDO), and
2 U of recombinant Taq polymerase (Perkin
Elmer/Cetus Norwalk CT). Hot start was per-
formed by heating samples to 95°C for 5 minutes
followed by addition of Taq DNA polymerase en-
zyme and cycling as follows: denaturation at 94°C
for 2 minutes, annealing at 46°C for 2 minutes,
increasing to 55°C over 1 minute, and elongation
at 72°C for 1 minute. Thirty cycles were per-
formed on a thermocycler (Perkin-Elmer/Cetus,
Norwalk CT) followed by a final elongation at
72°C for 7 minutes. PCR with the L1 primers gen-
erates a 600 base pair fragment and was per-
formed as described by Shamanin et al21 with 2
pairs of degenerate consensus primers (“A” and
“C”; and “B” and “C”). PCR products were run on
2% agarose gels, stained with ethidium bromide,
and photographed.
Southern Blot Hybridization. After denaturing
and neutralization, PCR products were trans-
ferred from agarose gels onto nylon membranes
(Amersham, Arlington, IL). E1 amplified frag-
ments from each of the types were a-32P-random
labeled and used as probes. The E1 membranes
were hybridized against a mixed probe for HPV
types 16 and 18 and then against a mixed probe
for types 31, 33, and 35. Hybridization was per-
formed overnight at 60°C under nonstringent con-
ditions (Tm-40°C) in 6 × SSC, 0.5% SDS, 5 × Den-
hardt’s, and 300 mg/mL of RNA. Membranes were
washed twice at 60°C in 6× SSC and 0.1% SDS
and exposed to film for at least 24 hours. The L1
PCR products were hybridized at 37°C with a
a-32P-end labeled degenerate oligonucleotide
probe as described.21 Membranes were washed
twice at 37°C in 6× SSC and 0.1% SDS and ex-
posed to x-ray film for at least 24 hours.
HPV Typing. Samples that were positive for HPV
DNA after Southern blot hybridization were
typed by use of oligonucleotide probes derived
from the E1 region that are type specific for HPV
16, 18, 31, 33, 35, 45, and 52. Probes were end-
labeled with g-P32 and hybridized under the con-
ditions described previously, hybridized at 60°C
in 6× SSC, 0.5% SDS, 5 × Denhardt’s, and 300
mg/mL of RNA. Membranes were washed twice
under nonstringent conditions (Tm-5°C) in 0.64 ×
SSC and 0.1% SDS and exposed to film for at least
24 hours. Six samples in which HPV DNA was
detected after low stringency hybridization did
not react with any of the type-specific probes. The
6 samples were then subjected to PCR with HPV
16 type-specific primers derived from the E6 ORF
as described by Shibata et al.22 One of 6 samples
was found positive for HPV 16. For the remaining
5, several attempts to reamplify and clone the
PCR products failed.
Statistical Analysis. Before the study, sample
sizes necessary to achieve statistical power of 80%
were calculated on the basis of the overall preva-
lence of HPV in SCCHN cited in the literature
(20%–30%) and on preliminary studies in our
laboratory finding HPV in 6 of 9 (67%) “young”
SCCHN patients. Chi-square tests, gamma sta-
tistics, and Spearman correlation coefficients
were applied to explore the relationship between
age and the other variables (tobacco and alcohol
use, site of disease, and stage of disease) and be-
tween HPV status and these variables. P values
less than .05 were considered to be significant.
Kaplan-Meier estimates of survival, stratified by
age and by HPV status, were obtained. P values
for the corresponding log rank tests were consid-
FIGURE 1. HPV type 16 viral gene map showing the ORFs on the
viral 7.9 kilobase dsDNA circular genome. “E” represents the
early genes and “L” represents the late genes.
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ered significant if less than .05. Cox proportional
hazards model was used to explore the effect of
variables (HPV, age, smoking history, ethanol
history, stage, and site) on patient survival.
RESULTS
Specimens from 14 “young” (age <50; range, 24–
48; median, 39) and 14 “old” (age >50; range, 50–
75; median, 66) SCCHN patients matched on the
basis of tumor site, and 4 additional “old” patients
were analyzed for the presence of HPV DNA.
Characteristics of these patients are shown in
Table 1. Most patients were exposed to known
HNC carcinogens, including 84% with a history of
tobacco use, 48% with frequent alcohol consump-
tion, and 39% with occasional alcohol consump-
tion. Tumors were of various sites, including 20
oral cavity or oropharyngeal tumors, 9 laryngeal
tumors, and 1 hypopharyngeal tumor. Most pa-
tients were initially seen with advanced stage tu-
mors (91% were stage III and IV). Overall follow-
up ranged from 6 to 50 months, with an average of
23.2 months. When broken down in to groups
studied, the average follow-up for young patients
was 24.9 months (median, 24), for old patients
21.4 months (median, 22), for HPV-positive pa-
tients 27.3 months (median, 26), and for HPV-
negative patients 19.7 months (median, 21). At
the time of last contact 17 patients had no evi-
dence of disease, 4 were alive with their disease,
and 11 were dead of their disease. Patients who
had no evidence of disease had an average follow-
up of 34.1 months (median, 29).
The overall prevalence of HPV DNA detected
in the samples was 47% (15 of 32). Fourteen of the
32 (43.5%) specimens were positive for HPV DNA
with the E1 primers, whereas 12 of the 32 (37.5%)
were positive with the L1 primers (Table 2).
Table 1. Patient data







1 Young Oral 4 No None + 50 AWD
4 Young Oral 1 No Frequent − 33 NED
11 Young Oral 4 Yes Frequent + 41 NED
12 Young Oral 4 Yes Occasional − 9 DOD
14 Young Oral 3 Yes Frequent − 21 NED
15 Young Oral 4 No Occasional + 9 DOD
17 Young Oral 4 Yes Occasional − 11 DOD
18 Young Oral 4 Yes Occasional − 44 NED
21 Young Larynx 4 Yes Occasional + 22 NED
25 Young Larynx 4 Yes Frequent − 15 DOD
28 Young Larynx 4 Yes Frequent + 35 NED
30 Young Oral 3 Yes Occasional − 6 DOD
31 Young Oral 3 Yes Occasional + 37 NED
32 Young Oral 4 Yes Occasional + 26 NED
2 Old Oral 3 No Frequent + 26 NED
3 Old Oral 4 Yes None − 7 DOD
5 Old Oral 4 Yes Frequent − 13 DOD
6 Old Oral 4 Unknown Unknown + 15 DOD
7 Old Oral 4 Yes Frequent − 29 NED
8 Old Oral 2 Yes None + 31 NED
9 Old Oral 4 Yes None + 22 NED
10 Old Larynx 3 No Frequent − 25 AWD
13 Old Oral 3 Yes Occasional + 12 AWD
16 Old Oral 3 Yes Occasional + 22 NED
19 Old Oral 1 Yes Frequent − 21 AWD
20 Old Oral 4 Yes None − 12 DOD
22 Old Larynx 4 Yes Occasional − 16 DOD
23 Old Larynx 4 Yes Occasional − 29 DOD
24 Old Larynx 3 Yes Frequent + 31 NED
26 Old HP 3 Yes Frequent − 22 NED
27 Old Larynx 4 Yes Frequent − 22 NED
29 Old Larynx 4 Yes Frequent + 31 NED
Abbreviations: Age: young = age <50, old = age $ 50; Site: oral, oral cavity and oropharynx, HP, hypopharynx; Status of disease: AWD, alive with disease,
NED, no evidence of disease after treatment; DOD, dead of disease.
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Three samples (patients 6, 28, 29) were positive
with the E1 primers only, and 1 (patient 1) was
positive with the L1 primers only. The concor-
dance between the two primer sets was 87.5%. On
ethidium bromide–stained gels of the E1 and/or
L1 PCR products, 9 of 15 (60%) of HPV DNA–
positive samples exhibited a band at the expected
850 base pair or 600 base pair size, respectively
(Fig. 2). All of them were confirmed to be positive
by Southern blot hybridization (Fig. 3). In addi-
tion, 6 of 15 (40%) samples that did not exhibit a
band on ethidium bromide–stained gels were
found to be positive for HPV DNA after Southern
blot hybridization. This high percentage indicates
that HPV is often present in very low copy num-
bers in SCCHN.
For HPV typing all positive samples were hy-
bridized with HPV type-specific oligonucleotide
probes derived from the E1 region. Eight of the 15
positive samples were found to be HPV type 16
and 1 of 15 positive samples was found to be HPV
type 18 by this method. Because patient 1 was
positive for HPV only with the L1 primers and not
the E1 primers, an alternate method of typing
was needed. PCR with HPV-16 type-specific prim-
ers derived from the E6 ORF followed by South-
ern blot hybridization with a type 16–specific oli-
gonucleotide probe as described by Shibata et al22
was performed on patient 1 and on the other 5
samples that remained untyped (patients 15, 21,
24, 28, 29). Patient 1 was found positive for HPV-
16 E6, and the remaining 5 were found negative
for HPV-16 E6. For these 5, several attempts at
reamplification of the E1 PCR and multiple at-
tempts to clone and sequence the HPV DNA were
unsuccessful. Interestingly, 4 of 5 were laryngeal
cancer specimens. Also of note is that all 5 un-
typed samples were found to be weakly positive
Table 2. HPV type and detection by primer set among
HPV-positive patients
Patient
HPV detection by primer set
HPV typeE1 primers L1 primers
1 − + 16
2 + + 16
6 + − 18
8 + + 16
9 + + 16
11 + + 16
13 + + 16
15 + + Untyped
16 + + 16
21 + + Untyped
24 + + Untyped
28 + − Untyped
29 + − Untyped
31 + + 16
32 + + 16
FIGURE 2. Representative E1 and L1 PCR products shown after electrophoresis on a 2% agarose gel
and ethidium bromide staining. PCR with E1 primers produces an 850-base pair (bp) fragment (arrow
a) and with L1 primers produces a 600-bp fragment (arrow b). Nonspecific amplification of human DNA
occurs with the L1 primers producing the fragment slightly larger than the desired 600-bp band. Lane
1, Molecular marker containing fX174 RF DNA/Hae III Fragments. Lane 2, Patient 31 showing an
850-bp band after E1 PCR. Lane 3, Patient 32 showing an 850-bp band after E1 PCR. Lane 4, Patient
28 showing no band after E1 PCR. Lane 5, Positive control, Caski cell line (contains HPV 16), showing
an 850-bp band after E1 PCR. Lane 6, Negative reagent control, water replaces DNA, after E1 PCR.
Lane 7, Patient 1 showing a 600-bp band after L1 PCR. Lane 8, Negative control, cell line 293 (known
HPV negative), after L1 PCR. Lane 9, Positive control, purified HPV 4 plasmid, showing a 600-bp band
after L1 PCR.
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for the presence of HPV DNA only under non-
stringent hybridization conditions using a mixed
probe. We did not specifically probe for types 6
and 11 because in our experience these types am-
plify well with the E1 primers and have a strong
cross-reactivity with the mixed probes. Overall
60% (9 of 15) of the positive samples were HPV
type 16, 6.6% (1 of 15) were HPV type 18, and
33.3% (5 of 15) remained untyped (Table 2).
When stratified by age, the prevalence of HPV
DNA detected was 50% (7 of 14) for the “young”
patients compared with 44% (8 of 18) for the “old.”
The odds of detecting HPV DNA in the young pa-
tients was 1.25 times (95% CI 4 [0.3, 5.1]) that
for the old patients. Although the sample size is
small and larger studies are needed, the data pro-
vide preliminary evidence to suggest that HPV is
not more prevalent in “young” than “old” patients.
The type of HPV found in the “young” and in the
“old” groups also did not differ significantly. Of
those that could be typed, the “young” consisted of
four HPV type 16 specimens, whereas the “old”
group consisted of 5 HPV type 16 and 1 HPV type
18 specimen. Three of the 5 specimens that re-
mained untyped were from “young” patients and
two were from the “old” patients. Site of disease
was a matching factor in the study design so did
not differ between the age groups. There was also
no statistical difference between the age groups in
regard to tobacco (p 4 .25) or alcohol (p 4 .15)
exposure, or stage of disease (p 4 .68). However,
given the retrospective nature of the study, alco-
hol and tobacco use could only be generally quali-
fied and could not be categorized by amount and
duration of use. Being of “young” age also did not
result in a statistical difference in survival com-
pared with the older group (p 4 .88, log rank
test).
The samples were divided into HPV DNA–
positive and HPV DNA–negative groups (regard-
less of age) and analyzed with these same vari-
ables. There was no statistical difference in
regard to tobacco (p 4 .61) or alcohol (p 4 .86)
exposure, site of disease (p 4 .61), or stage of
disease (p 4 .36) according to HPV status.
Univariate and stepwise Cox proportional
hazards modeling were used to identify factors
predictive of survival among the variables ana-
lyzed: HPV, age, smoking history, alcohol expo-
sure, stage, and site. No inferences could be made
on stage because there were no failures in the
stage I/II group and only one failure in the stage
III group. Only HPV (p 4 .02 was statistically
significant in univariate log rank analysis. Mul-
tivariate Cox regression modeling revealed that
survival in patients with HPV-positive SCCHN
was statistically longer than that for the HPV-
negative patients (p 4 .01, relative risk [RR] 4
0.13, 95% CI [0.03, 0.61]).
DISCUSSION
In our study, we attempted to determine whether
HPV DNA was detected more frequently among
“young” compared with “old” patients with SC-
CHN. It is recognized that this study is an explor-
atory investigation limited by small sample size.
However, our preliminary results suggest that
the prevalence of HPV DNA detected in the
“young” group did not statistically differ from that
in the “old” group. This suggests that HPV may
play a similar role in both groups. The difference
in exposure to tobacco and alcohol, in gender dis-
tribution, and in the observed aggressiveness of
SCCHN in the “young” patients have led many to
believe that the “young” may comprise a biologi-
cally and/or etiologically distinct group of SCCHN
patients.15,18 Many groups have searched for etio-
logic factors contributing to the development of
SCCHN in this population, yet no factors have
FIGURE 3. Representative 850-bp E1 PCR products shown after
Southern blot hybridization probed with a mixture of random-
labeled E1 amplified fragments of HPV 16 and HPV 18. Lane 1,
Negative reagent control, water replaces DNA in PCR. Lane 2,
Patient 30, negative for HPV. Lane 3, Patient 31, positive for
HPV. Lane 4, Patient 32, positive for HPV. Lane 5, Patient 28,
positive for HPV after Southern hybridization, but not visualized
after PCR alone (Fig. 2). Lane 6, Negative control, cell line 293
(known HPV negative). Lane 7, Positive control, purified HPV 4
plasmid.
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been shown to be conclusive. In this study we
found the presence of HPV DNA also does not
appear to distinguish the “young” population from
the “old”. One problem that occurs when studying
the “young” population is that studies are statis-
tically inconsistent because of the arbitrary age
used to define “young.”17 Several recent studies
have used age 4014,16,17 or even age 3513 as the
cut-off. Although we chose to use age 50, it should
be noted that changing our boundary to age 40
still would not have resulted in a statistical dif-
ference between the groups and actually would
reduce the prevalence of HPV DNA among the
“young” to 33.3%.
The fact that 50% of the “young” and 44.4% of
the “old” group were positive for HPV indicates
that HPV may be an important factor in the
pathogenesis of SCCHN. Many clues as to how
HPV may contribute to oncogenesis in SCCHN
have come from studies of carcinomas of the geni-
tal tract. In this disease HPV types 6 and 11 are
associated with benign proliferative lesions and
are considered “low risk.” Others, predominantly
types 16 and 18, are associated with preneoplastic
lesions and carcinomas and are considered “high
risk.”
The difference in oncogenic potential may be
due to type-specific differences in the E6 and E7
proteins.23 The E6 protein is an oncoprotein that
can complex with the p53 protein and promote its
degradation.23 The E7 protein similarly can com-
plex with the retinoblastoma (Rb) protein and in-
activate it.24 Both p53 and Rb are important tu-
mor suppressor genes whose products maintain a
regulated cell cycle, cell division, and apoptosis.
Overall, studies on the expression of E6 and E7 in
SCCHN are lacking and are needed to establish
possible mechanisms. However, a recent study in
our laboratory analyzed a nasal inverted papil-
loma specimen and adjacent normal tissue, both
of which contained HPV-6 DNA. E6 and E7
mRNA expression was demonstrated in the in-
verted papilloma but not in the normal tissue,
supporting a role of HPV in the pathogenesis of
this neoplasm.25
We found the percentage of HPV type 16
among positive samples to be similar to that in
cervical cancer (55%–60%); however, the number
of HPV-positive samples that were types other
than those tested for in this study is about fivefold
greater. These samples remain untyped despite
using probes for 7 of the most common types in
HNC and cervical cancer, and multiple attempts
to clone and sequence the viral DNA. These
samples were only weakly positive under non-
stringent conditions with a mixed probe, and
therefore were also not typical of types 6 or 11,
which, in our experience, react strongly both with
the E1 primers during PCR and with the mixed
probes. This may suggest there are novel HPV
types involved in HNC that differ from those
known in cervical cancer. It is interesting that 4
of the 5 untyped samples were laryngeal cancer
specimens, indicating that HPV type may differ
by tumor site. A review of HPV in laryngeal car-
cinoma revealed that in addition to identifying
types 6, 11, 16, and 18, one study also found HPV-
DNA–positive specimens of unknown type.11 An-
other study found HPV-30 to be present in SC-
CHN of the larynx.26 We did not use HPV-30
type-specific probes when attempting to type
these samples. Therefore, it is possible that these
samples may represent type 30 versus an as yet
uncharacterized HPV type in SCCHN.
Methodologically, we found the use of two sets
of consensus primers and Southern blot (SB) hy-
bridization resulted in increased HPV DNA de-
tection. We were able to detect HPV DNA in
46.9% of specimens. By use of only one set of con-
sensus primers, we would have missed 20% (3 of
15) of the positive samples. Other studies have
typically used only one primer set. A review of
published studies of SCCHN revealed the average
prevalence of HPV DNA using PCR was 34.5%.18
Most larger studies looking at a variety of HNC
sites and not at select sites or groups of patients
actually had a much lower detection, ranging
from 8% to 20% of samples.27 Others have also
recognized the importance of the use of multiple
consensus primers.28 In addition, PCR followed
by SB increases the sensitivity of detection by
1000-fold. Many samples positive after SB did not
show a visible band on agarose gel after PCR,
indicating that HPV is often present in low copy
numbers in SCCHN or that the tumor contains a
novel HPV type that has lower binding affinity for
our primers. The choice and number of consensus
primers used and whether SB hybridization of
PCR products is performed helps to explain some
of the vast variation in HPV DNA detection rates
cited in the literature.
The increased detection with the use of mul-
tiple consensus primers can be attributed to vary-
ing patterns of integration and deletion. For ex-
ample, HPV DNA from patient 1 was detectable
when PCR primers from the E6 and L1 ORFs
were used but was not detectable with primers
from the E1 ORF (Fig. 4). This result could be
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explained by a deletion in the E1 region or by
integration into the host genome such that the E1
region was interrupted. In cervical cancer, inte-
gration often disrupts expression of the E1 and
E2 ORFs, and therefore E1 and L1 are not neces-
sarily retained in all tumors.29 Another study of
invasive cervical cancers (stages IA to IVB) found
that comparison of the results for consensus L1
primers and type-specific E6-E7 primers indi-
cated the presence of L1 deletions in 41% of
samples.28 Therefore, even common HPV types
may not be detected with standard primers.
Integration is thought to be an important step
in tumor progression.30 Disruption of the E2 ORF
occurs regularly and is believed to alter transcrip-
tional modulatory proteins and favor enhanced
expression of the E6 and E7 genes.31 Studies ob-
serving integration sites in cervical cancer have
shown that HPV DNA is preferentially located
near protooncogenes, tumor suppressor genes,
and fragile sites whose disruption may contribute
to tumorigenesis. Similar studies in HNC have
been lacking; however, Kahn et al31 showed HPV
type 6a in a tonsillar cancer to be located on the
long arm of chromosome 24 at a fragile site that
may affect the protooncogenes Hox 11 and Lyt 10.
Further studies of HPV-DNA integration sites
and the host genes affected will be essential to
understanding the genes involved in tumor devel-
opment.
Although evidence is strong for the involve-
ment of HPV in the pathogenesis of SCCHN, HPV
infection alone seems insufficient to bring about
complete malignant transformation. For example,
in cervical cancer, the most studied HPV-induced
malignancy, many more women are infected with
HPV then the number that will have cancer de-
velop. However, immune status, genetic makeup,
and carcinogen exposure, to name a few, will in-
terplay in the progression of the disease.11 In fact,
many of our patients who were positive for HPV
also had tobacco and alcohol exposure as risk fac-
tors. Previous reports have suggested that be-
cause HPV has been detected in premalignant
and early stage SCCHN, it may act at an early
stage in tumor progression.9 Although our finding
of no significant relationship between HPV DNA
status and tumor stage supports that acquisition
of HPV is an early event, we had too few early
stage tumors in this study to conclude that HPV
DNA is equally present in early and late stage
tumors.
It is interesting that we found statistically im-
proved survival rates among the HPV DNA–
positive patients. Improved survival among HPV-
positive HNC has been noted by others as well.32
This may suggest that effects of HPV on the p53
and Rb proteins are not as detrimental as the
more classic mutations induced by other known
carcinogens such as tobacco and alcohol. It is pos-
sible, for example, that p53 inactivation may de-
pend on the level of HPV E6 present, and some
p53 may “escape” inactivation. However, the “pro-
tective effect” of being positive for HPV DNA on
patient survival may be caused by the underlying
heterogeneity in our study population, and cer-
tainly larger studies looking at the interrelation-
ships between HPV, tobacco, alcohol, and other
factors in a multivariate model must be under-
taken.
To better understand the mechanism of HPV
in SCCHN, future research is essential to deter-
mine whether there are novel types of HPV in-
volved in SCCHN; to determine whether viral
genes, in particular the E6 and E7 genes, are ex-
pressed in tumor cells; to determine the muta-
tional status and functional activity of the p53
and Rb genes HPV-positive compared with HPV-
negative patients; and to determine how viral in-
tegration sites affect oncogenesis. In cervical can-
cer, site of integration may be important for
tumorigenesis if it promotes expression of the
HPV E6 and E7 genes or if it affects host onco-
genes or tumor suppressor genes. Finally, even if
HPV prevalence does not differ by age, it will be
FIGURE 4. Kaplan-Meier survival estimates for patients with HPV
DNA–positive versus HPV DNA–negative SCCHN (p = .02).
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important to determine whether there are etio-
logic and/or biologic differences in SCCHN in the
“young” versus the “old” population. Answering
these questions may help to optimize therapeutic
management of SCCHN both in the “young” and
HPV-induced tumors of all age groups.
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